GDF10 is the target of variety tumor therapies including triple-negative breast cancer,[59] prostate cancer,[60] hepatocellular carcinoma,[61] lung cancer,[62] and oral squamous cell carcinoma.[63] GDF10 can be regulated by lncRNA ZFPM2-AS1 to enhance tumor invasiveness in hepatocellular carcinoma.[61] GDF10 was significantly up-regulated in GC tissue. The gene discussed is ZFPM2; the disease is prostate carcinoma.